TARO PHARMACEUTICALS U.S.A., INC.

Sun Pharmaceutical Industries has gained significant legal leverage after a US Court of Appeals vacated a preliminary injunction against its alopecia areata treatment Leqselvi, potentially enabling commercialization despite ongoing litigation with Incyte.

Sun Pharma is developing a promising obesity treatment GL0034, which demonstrated significant weight loss and metabolic improvements in Phase 1 trials.

Mankind Pharma has developed a pioneering GPR109 agonist as the world's first potential small-molecule oral treatment for obesity, currently advancing through Phase 2 trials in Australia.

Sezaby, a preservative-free phenobarbital formulation by Sun Pharmaceutical Industries, has been approved as the first FDA-sanctioned treatment specifically for neonatal seizures in both term and preterm infants.

The global basal cell carcinoma market is projected to grow from $5.48 billion in 2024 to $9.7 billion by 2035, exhibiting a CAGR of 5.34% according to IMARC Group research.

The CDSCO's Subject Expert Committee (SEC) has advised Sun Pharmaceutical Industries to conduct a Phase III clinical study on esaxerenone for resistant hypertension.

Resonance Health has secured a $13.8 million agreement with Sun Pharmaceutical to serve as the local Australian sponsor for a global clinical trial.

Sun Pharmaceutical Industries has received approval from the CDSCO panel to conduct a Phase III clinical trial of Aflibercept injection for neovascular age-related macular degeneration.

The DEA has approved Takeda Pharmaceuticals to increase production of Vyvanse by 24% to address ongoing shortages of ADHD medications.

The FDA has approved Leqselvi (deuruxolitinib) 8 mg tablets for treating adults with severe alopecia areata, offering a new oral option.